Home Overview Press Room Blog Publications For Students about us
Search

News Article

A DNA Sequencer in Every Pocketby Ed YongThe AtlanticApril 28th, 2016Oxford Nanopore Technologies, who severed financial ties with DNA sequencing monolith Illumina in 2013, is "desperately thinking of ways of bringing them down”, in particular: the MinION.
Scientists solve CRISPR’s ‘Energizer bunny’ problemby Sharon BegleySTATApril 27th, 2016A new CRISPR system called "CORRECT" stopped Cas9 from cutting again and again, and allowed researchers to edit one but not both copies of a target gene.
Meet The New CEO Of The $22 Billion Genomics Company You've Never Heard Ofby Christine FarrFast CompanyApril 27th, 2016Gene-sequencing giant Illumina is expanding to direct-to-consumer tests and perhaps brand partnerships, says new CEO Francis deSouza.
Editorial: Editing human genes the CRISPR wayby Editorial BoardThe Chicago TribuneApril 27th, 2016Can we trust scientists and governments to set ethical boundaries for research and therapeutic use — and then stick to them? We're skeptical.
Gay couple win custody battle against Thai surrogate motherby Oliver HolmesThe Guardian [US]April 26th, 2016The central juvenile and family court ruled in favor of American Gordon Lake, the biological father of 15-month-old Baby Carmen.
Dwarfism, Chemical Limb Lengthening, and Informed Consentby Joseph StramondoInternational Journal of Feminist Approaches to Bioethics BlogApril 25th, 2016CA biotech BioMarin Pharmaceuticals has completed Phase 2 of a drug clinical trial designed to "normalize" annual growth but not address health complications of dwarfism.
Inside the Hidden Global Supply Chain for Frozen Sperm, Eggs, and Embryosby Sarah ZhangWIREDApril 25th, 2016Ever-changing laws and attitudes, which vary not only country by country but within a country, can make transportation logistically difficult.
First Data from Anti-Aging Gene Therapyby Kerry GrensThe ScientistApril 25th, 2016Biotech company BioViva reports that an experimental treatment elongated its CEO Elizabeth Parrish’s telomeres.
God’s Red Pencil? CRISPR and The Three Myths of Precise Genome Editingby Jonathan LathamIndependent Science NewsApril 25th, 2016CRISPR is the latest platform in a 70-year-old "gospel of precision" used to justify moving quickly with new chemical and biological technologies, despite decades of disasters and unintended consequences.
US moves to sell gene-edited mushrooms fuel doubts over British ban on GM importsby Robin McKieThe Guardian April 23rd, 2016The USDA approved CRISPR-modified crops, but a European regulatory committee's delays are dismaying some UK researchers.
Displaying 1-10 of 4364  
Next >> 
Last Page » 
« Show Complete List » 


ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1122 University Ave, Suite 100, Berkeley, CA 94702 • • (p) 1.510.665.7760 • (F) 1.510.665.8760